These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 29318906)

  • 1. Cefiderocol: a novel siderophore cephalosporin.
    Choi JJ; McCarthy MW
    Expert Opin Investig Drugs; 2018 Feb; 27(2):193-197. PubMed ID: 29318906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection].
    Yamano Y; Morita I; Ariyasu M
    Nihon Yakurigaku Zasshi; 2024; 159(5):331-340. PubMed ID: 39218681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discovery of a New Siderophore Cephalosporin, Cefiderocol].
    Yamano Y
    Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
    Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
    Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria.
    AlMatar M; Albarri O; Makky EA; Var I; Köksal F
    Mini Rev Med Chem; 2020; 20(18):1908-1916. PubMed ID: 32811410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
    Bonomo RA
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S519-S520. PubMed ID: 31724046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
    Sato T; Yamawaki K
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S538-S543. PubMed ID: 31724047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefiderocol: Clinical application and emergence of resistance.
    Wang L; Zhu J; Chen L; Du H
    Drug Resist Updat; 2024 Jan; 72():101034. PubMed ID: 38134561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
    Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S
    Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.